Company data sheet · Abiomed
Abiomed: growth far beyond its economy.
- Industry
- Surgical & Medical Instruments & Apparatus
- Headquarters
- United States
- Sources
- SEC filings (1995–2023), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- October 18, 2026
- It outgrew its own economy many times over. Revenue rose from $0.3 billion in fiscal 2016 to $1 billion in fiscal 2022: 3.1 times as much. The US economy, counted the same way in money terms, grew about 31%. Whatever drove it, the economy around it does not account for growth of that size.
- Ahead of almost everyone like it. From 2016 to 2021, its revenue grew 132% in US dollars; the median among 688 large manufacturers grew 36%. It outgrew 87% of them.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $0.3 billion | $0 billion | |
| 2017 | $0.4 billion | $0.1 billion | |
| 2018 | $0.6 billion | $0.1 billion | |
| 2019 | $0.8 billion | $0.3 billion | |
| 2020 | $0.8 billion | $0.2 billion | |
| 2021 | $0.8 billion | $0.2 billion | |
| 2022 | $1 billion | $0.1 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 23 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (0 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.